Previous close | 0.0200 |
Open | 0.0200 |
Bid | 0.0000 |
Ask | 1.2700 |
Strike | 45.00 |
Expiry date | 2024-06-21 |
Day's range | 0.0200 - 0.0200 |
Contract range | N/A |
Volume | |
Open interest | 53 |
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Medtronic Plc (NYSE:MDT) reported fourth-quarter 2024 sales of $8.59 billion, beating the consensus of $8.44 billion. Revenue increased 0.5%, as reported, and 5.4% organic. The company’s organic revenue results reflect broad-based growth across the company, with mid-single-digit or higher organic revenue growth in all four segments. The medical device maker reported adjusted EPS of $1.46, beating the consensus of $1.45. Related: Medtronic’s Latest Generation Of Transcatheter Aortic Valve Replace
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.